GlassScriptPhysician profile
Josey O Barmore
NPI 1700137296
$9,403.96
in general payments reported to CMS, 2019-2025
28 companies · $3,388 in 2025
The $3,388 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $1,560 · 2023: $1,037 · 2024: $2,420 · 2025: $3,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,844.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,409.54 | 2021-2025 | Embold Fibered, General - Embolics, General - Angiography |
| Bard Peripheral Vascular, INC. | $1,351.20 | 2021-2025 | Denali Vena Cava Filter, Venovo, Pristine |
| Medtronic, INC. | $728.71 | 2021-2025 | Venaseal, Osteocool Rf Ablation System, Closurefast |
| Penumbra, INC. | $722.73 | 2022-2025 | Indigo System |
| Inari Medical, INC. | $625.47 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $362.38 | 2025 | Otezla, Krystexxa, Repatha |
| Teleflex LLC | $325.90 | 2022-2025 | Arrow |
| Madrigal Pharmaceuticals | $275.28 | 2025 | Rezdiffra |
| Jazz Pharmaceuticals INC. | $236.14 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $231.31 | 2022-2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $229.76 | 2021-2025 | |
| Terumo Medical Corporation | $201.04 | 2021-2024 | Azur Cx Detachable |
| Coloplast Corp | $176.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $171.59 | 2024 | Airsupra |
| Stryker Corporation | $168.46 | 2022-2025 | Spinejack |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $148.67 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Ajovy |
| Novo Nordisk INC | $119.55 | 2021 | |
| Mayne Pharma Commercial LLC | $118.49 | 2025 | |
| Genzyme Corporation | $111.00 | 2022 | |
| Abbvie INC. | $101.47 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.88 | 2022 | |
| Ascensia Diabetes Care US INC. | $97.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.65 | 2023 | Sotyktu |
| Merz North America, INC. | $76.41 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.29 | 2024 | |
| Angiodynamics, INC. | $23.11 | 2021 | |
| Smith+Nephew, INC. | $16.00 | 2024 | Renasys Touch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josey Barmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.